To read the full story
Related Article
- Chuikyo Ends Debate on FY2016 Reimbursement Policy Reform; Price-Based Penalty for Suspended Firms Not in Recommendation
February 4, 2016
- Chuikyo Discusses Optimizing Health Coverage for Poultices, Vitamins
December 14, 2015
- MHLW Asks Chuikyo to Revise Evaluation for Antipsychotic Therapies in Large Dosages without Adequate Guidance
October 26, 2015
- Chuikyo Subcommittee OKs 70% Threshold for DPC Incentive
October 16, 2015
- Chuikyo Payer and Doctor Reps Exchange Barbs on Spike in Generic Brand-Specified Scripts
October 8, 2015
- JPWA Calls for Fair Sharing of Distribution Costs for Premium-Granted Products
October 1, 2015
- Japan Eyes Linking Dormant Pricing Premium with Sakigake System, Upping Rate to 20% at Maximum
July 24, 2015
- Chuikyo Subcommittee OKs Plan to Draft GL for Analyzing Cost-Effectiveness; QALY Expected to Be Main Index
July 24, 2015
- Drug Pricing Organization Proposes Re-Pricing of Products with Huge Sales
July 23, 2015
- MHLW to Seek “Candidate Drug Lists” for Patient-Initiated Mixed Care from Medical Societies
July 9, 2015
- FY2015 Survey on Generic Use to Get Underway, Results Out in Autumn
July 9, 2015
- Univ. of Tokyo Prof. Tanabe Elected as Chuikyo Chairman
June 25, 2015
- HTAs Likely to Be Used for Re-Pricing of Listed Medicines
June 25, 2015
- Abe of JPA Proposes Exempting Ordinary Pharmacies from Medical Fee Cut Rule: Chuikyo
June 12, 2015
- NHI Price Revision in FY2017 and Annual NHI Price Revision Should Be Discussed Separately: Shirakawa
June 11, 2015
- Chuikyo Begins Discussions on FY2016 NHI Pricing Reform; Drug Pricing Organization to Present Views at Next Meeting
June 11, 2015
- Pay Heed to Company Burdens for Cost-Effective Evaluations, Kamoya Tells Chuikyo
May 28, 2015
- MHLW Eyes Budget Request to Set Up Cost-Effective Analysis Regime, Report Due Out Summer
May 28, 2015
REGULATORY
- Zepbound in Line for OSA Approval after Key Panel Nod
April 27, 2026
- LDP Team Urges Patent-Period Price Maintenance, CEA Review in Growth Strategy Proposal
April 27, 2026
- Takaichi Says Govt to Weigh Response to MFN Drug Pricing Policy
April 27, 2026
- Nitrosamines Found in Duloxetine, Diltiazem; Panel Sets Intake Limits
April 27, 2026
- Health Insurance Reform Bill Clears Lower House Committee, Draws Backlash
April 27, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





